Literature DB >> 6389648

Further evaluation of local intranasal immunotherapy with aqueous and allergoid grass extracts.

J W Georgitis, W F Clayton, J I Wypych, S H Barde, R E Reisman.   

Abstract

In a double-blind study, 45 grass-allergic patients received local nasal immunotherapy (LNIT) with either aqueous mixed-grass extract, formaldehyde-treated, mixed-grass extract (allergoid), or histamine placebo. Twenty-four patients received LNIT for a second successive year, and 21 patients received LNIT for the first year. The aqueous extract-treated patients had significantly lower symptom-medication scores than either allergoid- or placebo-treated subjects. There was no difference in symptom-medication scores in patients receiving allergoid and placebo treatment or in patients receiving 1 and 2 yr of LNIT. The aqueous extract stimulated a rise in serum grass-specific IgE. There was no serum or local antibody response after allergoid-extract treatment. Postseasonal rises in serum-IgE titers were observed in all three groups. These data suggest that LNIT with aqueous mixed-grass extract significantly reduces the symptoms of allergic rhinitis. The allergoid grass extract was ineffective in the second year of treatment. No cumulative effect of LNIT could be demonstrated in successive years of therapy.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6389648     DOI: 10.1016/0091-6749(84)90232-x

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  3 in total

1.  Effects of local nasal immunotherapy in allergic airway inflammation: Using urea denatured Dermatophagoides pteronyssinus.

Authors:  Sheng-Jie Yu; En-Chih Liao; Jaw-Ji Tsai
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Local nasal specific immunotherapy for allergic rhinitis.

Authors:  Giovanni Passalacqua; Giorgio Walter Canonica
Journal:  Allergy Asthma Clin Immunol       Date:  2006-09-15       Impact factor: 3.406

Review 3.  Allergen immunotherapy: routes, safety, efficacy, and mode of action.

Authors:  Jillian Leigh Hochfelder; Punita Ponda
Journal:  Immunotargets Ther       Date:  2013-07-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.